PQA, a non-profit organization, develops and maintains medication use performance measures, including proportion of days covered (PDC) medication adherence metrics used by the Centers for Medicare & Medicaid Services Part D Drug Benefit, the Health Insurance Market Quality Rating System, URAC and other industry and government organizations. PQA metrics also are used to calculate the star ratings for Medicare Advantage and commercial exchange plans.
Allazo forecasts patients’/residents’ medication adherence, predicting how to improve adherence and determining the effects of improved adherence on future healthcare costs and clinical outcomes. “Through this partnership, Allazo’s research will help determine ways to expand the settings of clinical care for use of PQA’s medication adherence metrics,” Woody Eisenberg, senior vice president for performance measurement and strategic alliances for PQA, said in a statement. “One objective of this research will be to identify ways in which the adherence metrics can be harmonized with other existing metrics used within accountable care models that can lead to measureable improvements in clinical outcomes.”
Allazo’s CEO, Clifford Jones, added: “PQA is an extremely important standard-setting body for medication adherence. We are happy to be working directly with PQA to improve the way medication adherence is measured.”